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Abstract. The poor prognosis of Ewing's sarcoma (EWS), 
together with its high lethal recurrence rate and the side-effects 
of current treatments, call for novel targeted therapies with 
greater curative effectiveness and substantially reduced 
side-effects. The oncogenic chimeric protein EWS/FLI1 is the 
key malignancy driver in most EWSs, regulating numerous 
target genes, many of which influence cell cycle progression. It 
has often been argued that targeting proteins regulated directly 
or indirectly by EWS/FLI1 may provide improved therapeutic 
options for EWS. In this context, our study examined FoxM1, 
a key cell cycle regulating transcription factor, reported to be 
expressed in EWS and influenced by EWS/FLI1. Thiostrepton, 
a naturally occurring small molecule, has been shown to selec-
tively inhibit FoxM1 expression in cancer cells. We demonstrate 
that in EWS, in addition to inhibiting FoxM1 expression, thio-
strepton downregulates the expression of EWS/FLI1, both at the 
mRNA and protein levels, leading to cell cycle arrest and, ulti-
mately, to apoptotic cell death. We also show that thiostrepton 
treatment reduces the tumorigenicity of EWS cells, significantly 
delaying the growth of nude mouse xenograft tumors. Results 
from this study demonstrate a novel action of thiostrepton 
as inhibitor of the expression of the EWS/FLI1 oncoprotein 
in vitro and in vivo, and that it shows greater efficacy against 
EWS than against other tumor types, as it is active on EWS cells 
and tumors at concentrations lower than those reported to have 
effective inhibitory activity on tumor cells derived from other 
cancers. Owing to the dual action of this small molecule, our 
findings suggest that thiostrepton may be particularly effective 
as a novel agent for the treatment of EWS patients.
Introduction
Ewing's sarcoma, a cancer predominantly affecting chil-
dren and young adults, is a highly aggressive disease, with 
25-30% patients exhibiting metastases at diagnosis (1-3). The 
rate of lethal recurrence is high in EWS patients and despite 
multimodal therapeutic regimens combining intensive treat-
ments with chemotherapy, enhanced surgical procedures, and 
advanced radiotherapy, the 5-year disease-free survival rate for 
patients with localized EWS is only 60-70%, while for those 
with metastatic disease it drops down to 30% (2,4). The poor 
prognosis of EWS in addition to long-term side-effects of 
chemotherapy and radiation warrant the need for novel targeted 
therapies, which would minimize or eliminate side-effects 
including developmental anomalies, elevated risk of recur-
rence, or increased incidence of secondary malignancies.
EWS is cytogenetically characterized by the presence 
of a reciprocal translocation t(11;22)(q24;q12), that generates 
chimeric genes resulting from joining the 5' half of the EWS 
gene and the 3' half of a gene belonging to the ETS family of 
transcription factors, most frequently the FLI1 gene. These 
hybrid EWS/FLI1 genes, which are present in about 90% of 
EWS cases, are heterogeneous with regard to the location of 
the translocation junction, having different breakpoints (1). 
Nevertheless, regardless of the fusion type, all EWS/FLI1 
proteins act as aberrant transcription factors that are respon-
sible for the highly malignant phenotype and poor prognosis 
for EWS (1). The transcriptional activation domain of EWS and 
the DNA binding domain of FLI1 enable the EWS/FLI1 protein 
to regulate numerous target genes involved in various cellular 
functions, some of which are critical for the development of 
EWS (5,6). Gene expression profiling demonstrated that many 
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regulated genes are indirect targets of EWS/FLI1, suggesting 
that EWS/FLI1-mediated oncogenesis results from direct and 
indirect mechanisms (7-9). A key characteristic of transformed 
cells is their alteration of cell proliferation (10), with deregu-
lation of genes involved in controlling cell cycle being often 
the cause for unrestrained proliferation, ultimately leading to 
oncogenesis (11). The oncogenic nature of EWS/FLI1 makes 
it a putative candidate to alter the cell cycle, either directly 
or indirectly, to promote EWS growth (12). A recent study 
using both patient-derived cell lines and tumor samples from 
individual EWS patients demonstrated that many EWS/FLI1 
upregulated genes do have roles in cell cycle control (13).
The forkhead box (Fox) proteins are evolutionarily conserved 
transcription factors possessing a conserved DNA-binding 
domain (DBD), or forkhead box. These proteins, which have 
been grouped into 19 families (Fox A-S), are involved in various 
cellular processes including growth and differentiation, embryo-
genesis, metabolism, development, apoptosis, migration and 
invasion (14). Due to the importance of Fox proteins not only 
in development, but also in adult organisms, a loss or gain of 
function for Fox genes can impact cell fate and development. It is 
therefore not surprising that deregulation of Fox genes have been 
reported in several genetic disorders as well as in cancer (14,15). 
Gene expression studies involving EWS/FLI1 knockdown 
in EWS samples have shown regulation of Fox genes, with 
FoxM1 being significantly downregulated upon knockdown 
of EWS/FLI1 (13,16). FoxM1 has a well characterized role in 
cell cycle progression through regulation of the G1/S and G2/M 
phases of cell cycle (17,18), but has also been characterized as an 
oncogene, with aberrant expression in a variety of cancers (19-25). 
FoxM1 has been proposed to be involved with uncontrolled cell 
division in early stages of tumorigenesis (21,26,27), and increased 
expression of FoxM1 remarkably correlates with progressive 
cancer stages (20,23,24,27). Thiostrepton, a natural product 
with antibiotic properties isolated from Streptomyces azureus, 
is known to inhibit the binding of FoxM1 to genomic target sites 
(28) and cellular studies showed that thiostrepton selectively 
targets breast cancer cells by inhibiting FoxM1 expression (29).
It has been recently reported that FoxM1 expression is 
elevated in EWS and that thiostrepton treatment reduced the 
viability of cultured EWS cell lines in a dose-dependent manner 
(30). However, its effect on tumor xenografts remained to be 
determined. Herein, we demonstrate that thiostrepton not only 
influenced FoxM1 expression in EWS, but also inhibited the 
expression of the EWS/FLI1 oncoprotein, reducing both their 
mRNA and protein levels. Thiostrepton exposure of EWS cells 
in culture caused their apoptotic cell death at doses much lower 
than those reported to cause similar effects against other cancer 
cell types. Moreover, thiostrepton treatment reduced the tumori-
genicity of EWS cells, significantly delaying tumor growth in 
nude mice xenografts. Collectively, these data strongly suggest 
that thiostrepton may be used to simultaneously target EWS/FLI1 
and FoxM1 in EWS cells and potentially be developed as a novel 
anticancer drug with enhanced efficacy against EWS.
Materials and methods
Reagents. DMEM, trypsin and antibiotics were purchased from 
Mediatech Inc. (Manassas, VA). The ECL western blotting 
substrate was purchased from Thermo Fisher Scientific Inc. 
(Waltham, MA); Alexa Fluor 488-conjugated secondary anti-
bodies and oligonucleotides were from Invitrogen (Carlsbad, 
CA); the protease inhibitor cocktail was from Roche Applied 
Science (Indianapolis, IN); CellTiter-Glo Luminescent Cell 
Viability Assay and Caspase 3/7 assay kits were procured from 
Promega (Madison, WI); Matrigel™ basement membrane 
matrix was from BD Biosciences (Franklin Lakes, NJ); ethidium 
homodimer (EthD-1) was from Cell Biolabs Inc. (San Diego, 
CA), and thiostrepton was procured from EMD-Millipore 
(Billerica, MA). Antibodies against FoxM1, Fli1 and actin were 
from Santa Cruz Biotechnology Inc. (Dallas, TX); antibodies 
against cyclin D1, PLK1, Akt, PARP, cleaved caspase 7, and 
survivin were from Cell Signaling Technology (Danvers, MA); 
the antibody against XIAP was from BD Bioscience; the anti-
Src antibody was from Epitomics Inc. (Burlingame, CA); and 
anti-Cep55 was from Abnova (Jhongli City, Taiwan, R.O.C.). 
Unless otherwise mentioned, chemicals used were of molecular 
biology or cell culture grade and were procured from Thermo 
Fisher Scientific Inc.
Cell lines, culture, treatment and viability assays. The EWS 
cell lines (A4573, SK-ES-1 and TC-71) and the breast cancer 
cell line (MCF-7) were maintained in DMEM supplemented 
with antibiotics and 10% fetal bovine serum. Cells were 
incubated at 37˚C in a humidified chamber with 5% CO2. 
Cells treated with thiostrepton (dissolved in DMSO) for 48 h 
were harvested and processed for experiments. Cell viability 
was measured using the CellTiter-Glo Luminescent Cell 
Viability Assay kit (Promega) in a 24- or 96-well plate format, 
according to the manufacturer's protocol. Following growth 
for the selected time points, luminescence intensity measured 
for each sample was plotted relative to values obtained for 
control cells. Data represent the average from at least three 
independent experiments.
Cell cycle analysis. EWS cells were harvested 48 h after 
exposure to thiostrepton, washed once in PBS, fixed in 70% 
ethanol in PBS, and stained with propidium iodide. Flow 
cytometric analysis was carried out on a FACScan instrument 
(Becton-Dickinson, San Jose, CA), performed at the Flow 
Cytometry/Cell Sorting Shared Resource of the Lombardi 
Comprehensive Cancer Center.
Reverse transcription-PCR. RNA extraction, reverse transcrip-
tion-PCR (RT-PCR) conditions, and PCR product analysis 
were carried out as described (31). Primer pairs 5'-ACAAGC 
CCAACAACAAGG-3' (forward) and 5'-ATCGGGATGCCA 
AAGAGG-3' (reverse) were used to amplify EWS/FLI-1, while 
5'-GCCAACCGCTACTTGACATT-3' (forward) and 5'-TCT 
CCTCTTTCCCTGGTCCT-3' (reverse) were used for FoxM1. 
Tubulin was used as internal control, with the primer set 
5'-GCAGATGCTTAACGTGCAGA-3' (forward) and 5'-GGCA 
TCCTGGTACTGCTGAT-3' (reverse). The number of cycles for 
PCR was adjusted to ensure that the reaction end-points 
remained within the exponential phase of product amplification, 
to get a semi-quantitative estimate of relative mRNA abundance.
Tumorigenicity assays. Tumorigenic activity was deter-
mined through xenograft assays carried out as previously 
described (31). Male immunodeficient, athymic nude 
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(BALB/c nu/nu) mice were obtained from Harlan Laboratories 
(Indianapolis, IN) and all animal work was done under 
protocols approved by the Georgetown University Animal 
Care and Use Committee. EWS cells (5x106 cells in 100 µl 
of serum-free medium) were mixed with 100 µl of Matrigel 
basement membrane matrix and injected s.c. into the poste-
rior flank of mice. Once tumors reached a mean volume of 
about 150 mm3, mice were divided into control and treatment 
groups (10 animals per group). Treatment groups received 
thiostrepton (given i.p. at a dose of 17 mg/kg), while control 
groups received i.p. injections of thiostrepton carrier solu-
tion (32) in equal volume. Animals were injected every third 
day from the initial injection of thiostrepton and tumors were 
measured every alternate day. At specified times during the 
treatment, or whenever tumors reached the maximum volume 
allowed by institutional tumor burden guidelines, the corre-
sponding animals were sacrificed by asphyxiation with CO2 
and tumors were excised for experimental purposes. Primary 
tumor volumes were calculated by the formula V = (1/2)a x b2, 
where a is the longest tumor axis and b is the shortest tumor 
axis. Data were plotted as mean values ± SE in quantitative 
experiments.
Western blot analysis. Cells were lysed with RIPA buffer 
containing protease inhibitors, and lysates were centrifuged at 
10,000 x g at 4˚C for 15 min. Tissues were first homogenized 
in RIPA buffer containing protease inhibitors, and lysates were 
centrifuged at 10,000 x g at 4˚C for 15 min. Lysates were subject 
to SDS-PAGE and the resolved polypeptides were transferred 
to PVDF membranes. Following transfer, the membranes 
were blocked with 5% skim-milk in PBST (PBS containing 
0.1% Tween-20) at room temperature for 1 h, and incubated 
overnight with gentle rocking at 4˚C with designated primary 
antibodies. Next, blots were washed with PBST and incubated 
at room temperature for 1 h with horseradish peroxidase 
(HRP)-conjugated secondary antibody, and the peroxidase 
activity was detected by enhanced chemiluminescence, using 
the ECL western blotting substrate.
Immunofluorescence analyses. For fluorescence studies, the 
control and treated cells were cultured on cover-slips, washed 
once in PBS and fixed with 4% paraformaldehyde in PBS for 
20 min at room temperature. Following fixation, the cells were 
washed in PBS and permeabilized with 0.2% Triton X-100 for 
10 min. Blocking was done in 10% normal goat serum (Vector 
Laboratories, Burlingame, CA) in PBS for 30 min and incu-
bated with FoxM1 (1:500 dilution) antibody for 1 h at room 
temperature. Cells were then washed twice in PBS for 10 min 
each, and incubated with Alexa fluor 488 conjugated anti‑rabbit 
IgG for 1 h at room temperature. The cells were washed twice in 
PBS for 10 min each, followed by DNA staining with DAPI for 
5 min, and finally washed once in PBS and once in deionized 
water before being mounted in Fluoro-Gel mounting medium 
(Electron Microscopy Sciences, Hatfield, PA) and viewed 
under a fluorescence microscope. Images were processed with 
ImageJ software.
Caspase activity assay. Caspase 3/7 activity in the treated cells 
was determined using the Caspase 3/7 assay kit from Promega, 
according to the manufacturer's protocol.
Statistical analysis. Unless otherwise indicated, RT-PCR 
and western blot analyses were repeated at least thrice. Data 
from densitometric quantification analyses were expressed 
as mean ± SD. For these and other assays involving statistical 
analysis, ANOVA or Student's t-tests were used to assess the 
significance of differences between groups or individual vari-
ables, respectively. p≤0.01 was regarded as significant.
Results
Thiostrepton inhibits the proliferation of EWS cells. 
Thiostrepton, a natural compound, has been shown to 
exert anti-proliferative effects against human cancer cells, 
mainly through inhibition of FoxM1 activity (28). In order 
to determine the efficacy of this compound on EWS cells, 
we examined dose-dependent effects of thiostrepton on 
the proliferation and/or viability of EWS cell lines A4573, 
SK-ES-1 and TC-71, selected as representative of the three 
major EWS/FLI1 translocation types (1). MCF-7, a breast 
carcinoma cell line in which the effects of thiostrepton 
had been already characterized (29), was used as a control. 
Cells were examined up to 48 h after treatment with various 
doses of thiostrepton. While, as expected, MCF-7 cells did 
not show substantial changes in morphology or viable cell 
counts following treatment with up to 2 µM thiostrepton, the 
three EWS cell lines were clearly susceptible to thiostrepton 
treatment (Fig. 1A), with viable cell numbers decreasing in 
all cases by ~50% upon treatment with 1 µM thiostrepton 
(Fig. 1B). Consequently, unless otherwise indicated, EWS 
cells were treated with 1 µM thiostrepton for 48 h for all 
subsequent experiments. FACS analyses showed that cell cycle 
progression was altered in the cultures of the three treated cell 
lines, with a decrease in the percentage of the cell populations 
traversing through S-phase and the accumulation of cells in 
either the G1 or the G2-M phase (Fig. 1C). Thiostrepton also 
caused marked morphological changes. A large proportion of 
treated cells showed a round morphology and detached from 
plates, while those still adhering to plates showed a spread 
out polygonal shape, unlike their control counterparts, which 
were rather rounded and smaller (Fig. 2A). Thiostrepton also 
induced a change in the organization of actin cytoskeleton in 
EWS cells, with an intense staining observed near the nuclear 
periphery of treated cells (Fig. 2B).
Thiostrepton inhibits the mRNA and protein expression of both 
FoxM1 and EWS/FLI1. Immunofluorescent detection revealed 
that FoxM1, which is predominantly localized in the nuclei 
of EWS cells, was substantially decreased when cells were 
treated with thiostrepton (Fig. 3A). This result was corroborated 
by western immunoblot analysis, which showed a significant 
decrease in FoxM1 expression (Fig. 3B). Accordingly, the 
expression levels of known FoxM1 downstream targets such 
as polo like kinase-1 (PLK-1), the 55-kDa centromeric protein 
Cep55, and cyclin D1 were also decreased following thio-
strepton treatment. It is noteworthy that thiostrepton treatment 
did not induce any significant change in the expression of Akt, a 
known regulator of FoxM1 expression (29). We also investigated 
the possible effect of thiostrepton treatment on the expression of 
EWS/FLI1, the key oncogenic protein driving EWS malignant 
progression. Interestingly, the levels of the EWS/FLI1 onco-
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protein were also markedly reduced in the treated cells (Fig. 3B), 
prompting us to examine if the levels of EWS/FLI1 mRNA were 
altered upon thiostrepton treatment. RT-PCR analyses following 
thiostrepton treatment for 48 h revealed that transcript levels 
of both FoxM1 and EWS/FLI1 were substantially diminished 
relative to those in untreated controls (Fig. 3C), indicating that 
thiostrepton treatment decreases the expression of both mRNA 
and protein not only of FoxM1, but also, and most importantly, 
of EWS/FLI1 in EWS cells.
Thiostrepton treatment inhibits the growth of EWS-derived 
tumors in vivo. The effects of thiostrepton on tumorigenicity 
were examined in vivo by s.c. injection of A4573 cells into nude 
mice and monitoring tumor growth. When tumors reached a 
Figure 1. Thiostrepton influences cell proliferation and induces cell cycle arrest in EWS cells. (A) The effect of increasing concentrations of thiostrepton on the 
proliferation of EWS cells (A4573, SK-ES-1 and TC-71) and breast cancer MCF-7 cells was determined by CellTiter-Glo Luminescent Cell Viability assay kit in a 
24-well plate format, according to the manufacturer's protocol (n=3). (B) Viable cell counts of EWS cells after 48-h treatment with 1 µM thiostrepton; histogram 
bars represent mean percentages of the viable cell counts; bars, SD (*p≤0.0001; n=4). (C) EWS cells were treated with 1 µM thiostrepton for 48 h and cell cycle 
analysis was done following propidium iodide staining (n=3). Ctrl and Thio correspond to control and thiostrepton-treated cells, respectively.
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volume of ~150 mm3 (around day 8) animals were randomized 
into two groups (n=10) and treated as described in Materials 
and methods. Subsequently, tumor growth was followed over 
a period of four weeks, measuring the volume every other day. 
Halfway through the treatment plan (day 16 after cell injec-
tions), tumor volumes in control mice had increased ~6-fold 
from the initiation of treatment, while their thiostrepton-
treated counterparts increased only ~1.7-fold, exhibiting a 
~3.5‑fold reduction (p≤0.0005), relative to controls (Fig. 4A). 
Around 22 days after the s.c. cell injections, when animals 
from control groups had to be sacrificed following Institutional 
Animal Care and Use guidelines on maximum allowable tumor 
burden, the thiostrepton‑treated tumors showed a significant 
decrease in size (Fig. 4B). Following sacrifice, the tumors were 
excised and their volumes determined. Measurements showed 
that tumors derived from control untreated cells increased 
~19-fold in comparison to their volume at the start of the treat-
ment, while those derived from cells treated with thiostrepton 
increased only ~4-fold, thus showing a ~4.75-fold difference 
in volume relative to the untreated controls (Fig. 4B inset). 
These data revealed that thiostrepton significantly hampers the 
growth of EWS tumors.
To examine whether the antitumor effects of thiostrepton 
treatment correlated with the expression levels of FoxM1, its 
downstream targets, and/or EWS/FLI1, we investigated these 
proteins by western immunoblot analysis of lysates prepared 
from xenograft tumors excised from control and treated 
animals. The data obtained agreed with our previous obser-
vations upon thiostrepton treatment of EWS cells, showing a 
decrease in the levels of FoxM1 and its downstream targets, 
as well as diminished levels of EWS/FLI1 in lysates from 
thiostrepton-treated tumors (Fig. 4C). Immunostaining for 
FoxM1 and EWS/FLI1 in paraffin‑embedded sections of xeno-
graft tumors show a decreased expression for both proteins in 
sections of tumors from thiostrepton-treated mice (Fig. 4D). 
Taken together, results indicated that the observed effects were 
Figure 2. Altered morphology with disrupted actin network in thiostrepton treated EWS cells. (A) Phase contrast micrographs from control and cells treated 
with 1 µM thiostrepton for 48 h, showing altered morphology for treated cells (bottom panels); scale bar, 100 µm. (B) Treatment with thiostrepton alters the actin 
cytoskeleton in EWS cells; images represent rhodamine-labeled phalloidin staining for actin and nuclear staining with DAPI for the indicated cell lines. Scale bar, 
100 µm. Ctrl and Thio correspond to control and thiostrepton-treated cells, respectively.
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a consequence of thiostrepton treatment, leading to decreased 
tumorigenicity of EWS cells.
Thiostrepton inhibitory effects on EWS proliferation and 
tumorigenicity are mediated by a caspase 7-dependent apop-
totic response. In addition to the effects on cell cycle described 
above, thiostrepton treatment appeared to induce a dose-
dependent extent of cell death, in agreement with the increased 
proportion of cells detected in the sub-G1 peak in thiostrepton-
treated cultures. Consequently, an initial assessment of cell death 
Figure 3. Thiostrepton reduces mRNA and protein expression of FoxM1 and EWS/FLI1. (A) Immunodetection of FoxM1 in thiostrepton-treated and control EWS 
cells. The image shows FoxM1 immunostaining (left column), nuclear staining with DAPI (center column) and their merged image (right column), for the cell 
lines indicated; scale bar, 100 µm; Ctrl and Thio correspond to control and thiostrepton-treated cells, respectively. (B) Immunoblot showing substantial reduction 
in levels of FoxM1 and some of its known downstream targets as well as in the levels of the EWS/FLI1 oncoprotein in thiostrepton-treated cells (+) relative to 
untreated (-) controls; β-actin was used as the loading control. (C) Thiostrepton treatment decreased the mRNA expression of FoxM1 and EWS/FLI1 in EWS cells 
relative to untreated controls, as detected through RT-PCR analysis; relative values for three independent experiments showing mean ± SD are depicted. Ctrl and 
Thio correspond to control and thiostrepton-treated cells, respectively.
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was made by using EthD-1 staining of cells in culture. These 
examinations revealed that the observed changes in morphology 
were accompanied by the induction of apoptosis (Fig. 5A). As 
thiostrepton has been described as an activator of caspases (29), 
we determined the levels of caspase 3/7 activity in thiostrepton-
treated cells and in the untreated controls. Results showed a 
3- to 6-fold elevation in caspase activity in all thiostrepton-
treated EWS cells (Fig. 5B). Consistent with the observed 
increase in caspase activity, western blot analyses revealed that 
thiostrepton caused PARP cleavage, decreased expression of 
XIAP and survivin, and the cleavage of caspase 7 in treated 
EWS cells (Fig. 5C) as well as in lysates of treated xenograft 
tumors (Fig. 5D), thus substantiating the results in vitro and 
in vivo. Although the in vitro caspase activity assays used did 
not distinguish between changes due to caspase 3 or caspase 7, 
the fact that cleaved caspase 3 could not be detected in samples 
of cells or tumors treated with thiostrepton using either western 
immunoblots, immunofluorescence or immunohistochemistry, 
supports the notion that thiostrepton induces the apoptotic death 
of EWS cells in culture and in xenograft tumors predominantly 
through a caspase 7-dependent mechanism.
Discussion
The genes regulated by the aberrant transcription factor 
EWS/FLI1 play crucial roles in oncogenesis and EWS devel-
opment (12,33). EWS/FLI1-regulated proteins have been 
frequently regarded as a source of potential therapeutic options 
for EWS patients. Gene expression studies involving EWS/FLI1 
knockdown in EWS cells showed regulation of Fox genes, 
with FoxM1 expression being significantly decreased after 
EWS/FLI1 downregulation (13,16). FoxM1 is involved in cell 
Figure 4. Thiostrepton treatment reduces the tumorigenicity of EWS cells. (A) Xenografts established by s.c. injection of A4573 cells in athymic (BALB/c nu/nu) 
nude mice were given i.p. dosage of thiostrepton (17 mg/kg) (n=10). Tumor growth in the animals was monitored on alternate days following s.c. cell injections, 
and statistically significant differences in tumor volume were noted for the treated sample around 22 days post‑injection (p≤0.00002). Arrows indicate days when 
the mice were subjected to thiostrepton injection. (B) Mice injected with A4573 cells and treated with vehicle or with thiostrepton were euthanized when tumors in 
control animals reached maximum allowable tumor burden (22 days), and tumors were excised and their volume measured. Inset shows images of representative 
tumors isolated at 22 days post s.c. cell injection. (C) Immunoblot showing the reduction in the levels of FoxM1 and some of its transcriptional targets as well as 
of the EWS/FLI1 oncoprotein in lysates from mice treated with thiostrepton relative to those from untreated animals; β-actin was used as loading control. 
(D) Sections of xenograft tumors excised from mice treated with vehicle or triostrepton were subjected to immunohistochemical analysis to detect FoxM1 or 
EWS/FLI1. Results showed decreased staining for both target proteins in tumors excised from thiostrepton-treated mice relative to those obtained from control 
animals. Scale bar, 50 µm. Ctrl and Thio represent control and thiostrepton-treated samples.
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proliferation, being expressed only in actively cycling cells under 
normal conditions, and regulating the expression a number of 
genes involved in cell cycle control (18,34,35). In addition to its 
involvement in uncontrolled cell division during early stages of 
tumorigenesis (21,26,27), elevated levels of FoxM1 have been 
found associated with progressive stages of increasing malig-
nancy in a variety of cancers (20,23,24,27). As overexpression 
of FoxM1 has been reported in more than 20 types of human 
cancer and is involved in multiple landmarks of cancer (36), the 
inhibition of FoxM1 activity is emerging as an attractive target 
for cancer therapy. Results in the current study provide strong 
evidence supporting the notion that the inhibition of FoxM1 is a 
possible therapeutic option for EWS patients.
Thiostrepton, a thiazole antibiotic, has been already identi-
fied as having anticancer activity (37), and a number of studies 
have demonstrated its cytotoxic effect through selective inhibi-
tion of FoxM1 on a wide variety of cancer cell lines (29,38,39). 
We studied the effect of thiostrepton on EWS cells and observed 
a better efficacy under identical conditions on EWS lines in 
comparison to a breast cancer cell line, for which the effect 
of thiostrepton had been previously characterized (Fig. 1A). 
Inhibition of FoxM1 altered cell cycle in EWS cell lines 
(Fig. 1C), corroborating the role of FoxM1 in cell cycle progres-
sion through G1/S and G2/M phases. The morphology of EWS 
cells was altered upon treatment with thiostrepton, manifested 
by their spontaneous detachment from the culture plates and by 
the modification in their actin cytoskeleton (Fig. 2). The altered 
actin organization may facilitate cell detachment, ultimately 
leading to cell death (40).
Loss of FoxM1 following thiostrepton treatment led to 
a concomitant decrease in the expression levels of proteins 
regulated by FoxM1, including PLK1, Cep55 and cyclin D1. 
However, proteins influencing FoxM1 expression were not 
changed, proving that the observed thiostrepton effects were 
due to alteration of signaling pathway(s) downstream of FoxM1 
(Fig. 3), with one remarkable exception. Interestingly, the 
mRNA and protein levels of the EWS/FLI1 oncoprotein were 
reduced upon treatment with thiostrepton (Fig. 3). The reduc-
tion in mRNA expression suggests that this regulation might 
be at the transcriptional level. Since it was previously reported 
that thiostrepton inhibits FoxM1 binding to its genomic target 
sites (28), we hypothesized that the small molecule might be 
associated in a similar interfering mechanism with EWS/
FLI1, leading to a reduction of the aberrant transcription factor. 
However, as our analysis of the 5' regulatory sequences (up to 
3,000 bp upstream of transcription initiation site) of the EWS 
gene indicated the absence of the major FoxM1 DNA-binding 
sites described to date (41,42), it seems that the effect of FoxM1 
on the levels of EWS/FLI1 mRNA may be the result of an indi-
rect mechanism. Although it is possible that such a mechanism 
may involve the downregulation of another transcription factor, 
the precise mechanism of EWS/FLI1 regulation needs to be 
elucidated. Nonetheless, the reduction in EWS/FLI1 in addi-
tion to the decrease in FoxM1 suggests that thiostrepton does 
efficiently block both oncoproteins, thus providing an important 
added value to its efficacy for the treatment of EWS.
Using a nude mouse xenograft system, we show that thio-
strepton efficiently decreases the tumorigenicity of EWS cells, 
evidenced by the significant delay in tumor growth as reflected 
by the much smaller (~5-fold) tumor volumes attained in 
Figure 5. Thiostrepton induces a caspase 7-dependent apoptotic response in 
EWS cells and tumors. (A) Detection of cell death in thiostrepton-treated 
EWS cells, using the cell viability indicator ethidium homodimer-1 (EthD-1); 
scale bar, 100 µm. (B) Determination of caspase 3/7 activity in control and 
thiostrepton-treated EWS cells; histogram bars represent mean fold changes in 
activity; bars, SD (*p≤0.003; n=3). (C) Immunoblot showing cleavage of PARP, 
reduction in XIAP and survivin, along with the detection of cleaved-caspase 7 
in lysates from control cells (-) and from thiostrepton-treated cells (+); β-actin 
was used as the loading control. (D) Immunoblot showing cleaved PARP, 
decreased survivin, and increased cleaved-caspase 7 in lysates from tumors 
derived from vehicle- or thiostrepton-treated animals; β-actin was used as 
the loading control. Wherever applicable, Ctrl and Thio represent control and 
thiostrepton-treated cells or animals, respectively.
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thiostrepton-treated animals relative to vehicle-treated controls 
(Fig. 4). Our data also reveal that an important factor in the 
mechanism of action of thiostrepton on the proliferation EWS 
cells in culture and the decreased tumorigenicity in vivo is the 
activation of a caspase-dependent apoptotic response primarily 
involving caspase 7 as the main cell death effector (Fig. 5). In 
this regard, our results on the effect of thiostrepton on EWS 
cells seems to differ from data in previous reports indicating the 
predominant involvement of caspases 3, 8 or 9 in the apoptotic 
processes promoted by thiostrepton treatment in human cell 
lines derived from a variety of other tumor types (29,43-46). 
However, our results agree with previous findings indicating that 
caspase 7 activation mediated EWS cell death after exposure to 
other anticancer agents (31). Taking together our results from 
EWS cell cultures and from tumorigenicity assays, it appears 
that the action of thiostrepton on EWS involves an effect on the 
cell cycle, by arresting the cells at the G1 and G2/M phases of 
the cell cycle, and ultimately triggering cell death.
Because overexpression of FoxM1 has been demonstrated 
to lead to deregulated cell growth, and FoxM1 has been found 
being overexpressed in many cancers, it has been frequently 
argued that targeting FoxM1 may provide an opportunity 
towards curbing tumorigenesis. In fact, it was earlier proposed 
that FoxM1 may be the ‘Achilles' heel’ of cancer (47). This notion 
is clearly supported by the wealth of information accumulated 
demonstrating that FoxM1 is involved essentially in most, if not 
all, processes associated with cancer progression (15,36). FoxM1 
is a uniquely suitable target for therapeutic intervention in many 
tumor types. Our findings showing that thiostrepton is highly 
active in vitro and in vivo against EWS not only by inhibiting 
FoxM1, but also, and most importantly, by downregulating the 
expression of the EWS/FLI1 oncoprotein, identify thiostrepton 
as a novel therapeutic agent with dual inhibitory activity against 
EWS. Although the precise mechanism by which thiostrepton 
promotes EWS/FLI1 downregulation remains to be elucidated, 
results from the current study strongly suggest that thiostrepton 
alone may show greater efficacy in the treatment of EWS than 
against other tumor types, as it exerts its inhibitory action 
on EWS cells and tumors at concentrations lower than those 
reported to be required for effective antitumor activity on other 
cancer types (44,45,48,49). In addition, the use of thiostrepton in 
combination with other drugs also known to target EWS/FLI1 
expression (50) may likely increase the therapeutic efficacy over 
currently available EWS treatments, thus improving the disease 
outcome for EWS patients.
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